ii view: negative reaction to GSK's guidance upgrade - interactive …

Jul 31, 2024 · GSK continues to expect a full-year 2024 dividend of 60 per share, up from 58p in 2023. Third-quarter results are scheduled for 30 October. ii view: Formed in 2000 via a merger …

CouponFollow Extension

6%
OFF

GSK: The Worst Is Finally Over (Rating Upgrade) - Seeking Alpha

2 weeks from now

Oct 10, 2024 · GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable at 12.4x. Explore more details here.

seekingalpha.com

13%
OFF

GSK Lifts Guidance After HIV, Cancer Treatments Boost Sales - MSN

2 weeks from now

GSK’s HIV sales grew 13% to £1.76 billion, boosted by strong demand for Dovato and Juluca treatments as well as long-acting medicines such as Cabenuva and Apretude.

msn.com

13%
OFF

GSK Lifts Guidance After HIV, Cancer Treatments Boost Sales

2 weeks from now

GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.

wsj.com

12%
OFF

GSK Hikes Guidance After Strong Third Quarter - Sharecast.com

2 weeks from now

Nov 1, 2023 · As a result of its performance, GSK upgraded its 2023 guidance and now anticipated a 12% to 13% increase in turnover, growth of 13% to 15% in adjusted operating …

sharecast.com

17%
OFF

Ii View: UK Drug Giant GSK Lifts 2023 Profit Hopes - Interactive …

2 weeks from now

Nov 1, 2023 · ii view: UK drug giant GSK lifts 2023 profit hopes. ... Guidance: Now expects full-year adjusted earnings growth of between 17% and 20%, up from 14% to 17% ... ii view: …

ii.co.uk

FAQs about ii view: negative reaction to GSK's guidance upgrade - interactive … Coupon?

Why did GSK's share price surge 6% Yesterday?

GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 2024 results, with a GBP 1.8 billion charge expected to impact the earnings per share by GBP 0.44. ...

Does GSK expect a risk-adjusted assessment of sales of relevant assets?

s of uncertainty than the Relevant Statements. As such, while GSK does not expect to achieve the aggregate amount of those estimated non-risk adjusted peak year sales, a risk-adjusted assessment of sales of relevant assets during the relevant periods is (as stated above) taken into account ...

How will GSK's settlement charge affect earnings?

GSK will recognise a charge of USD 2.3 billion, which includes both the already agreed upon settlements, along with charges for the still pending cases. The charge, will of course, have a negative impact on reported earnings. ...

What do GSK and Pfizer have in common in 2024?

Both GSK and Pfizer have had one thing in common in 2024 - their flagship new asset, an RSV vaccine, has run into some very tough problems. ...

How much will GSK's core operating profit grow?

Meanwhile, core operating profit—a closely watched measure of profitability—is expected to grow between 11% and 13%, up from 9% to 11% previously. For core earnings per share, GSK expects growth of 10% to 12% from 8% to 10% previously. ...